Counsel from Irell & Manella LLP, Sandoz and Bristol Myers Squib to Chair ACI's Paragraph IV Disputes this April in NYC
The Californer/10231890

NEW YORK - Californer -- American Conference Institute (ACI) is pleased to announce that the Honorable Kathleen M. O'Malley (Ret.) from Irell & Manella LLP, Neema Kumar from Sandoz, and Serena Farquharson Torres from Bristol Myers Squibb will be chairing the 18^th Annual Paragraph IV Disputes conference taking place live and in-person April 19-20, 2023, in New York City.

The Honorable Kathleen M. O'Malley (Ret.) comments, "This year's Paragraph IV Disputes conference comes at an important time. Our innovation and IP Ecosystem are under attack from a variety of sources, putting our economy, the future of our health care, and our strategic place in the world at risk. I look forward to discussing these risks and possible ways to minimize those risks with the talented pool of IP professionals the conference annually brings together. I am also personally pleased that I am being given the chance to conduct a dialogue with Judge Leonard Stark, my successor on the Federal Circuit. That will be a highlight of the Conference for me."

More on The Californer

• AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
• IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
• Long Beach Health Department Reaffirms Commitment to Infant Hepatitis B Protection
• Critical Reach Unveils Initiative to Equip Every U.S. School with Crisis Technology at No Cost
• Are You Hiring The Right Heater Repair Company in Philly?

Neema Kumar notes that, "A robust and predictable patent system is critical to incentivizing innovation while facilitating access and ensuring the long-term sustainability of lower cost critical medicines. Join industry leaders, members of the judiciary, key agency representatives and your colleagues as we discuss game changing legislation impacting our industry and patients, current Hatch-Waxman trends, pharmaceutical policy initiatives and much more."

Serena Farquharson Torres adds, "Being on the forefront of pioneering research makes me both excited and hopeful for our patients yet somehow uncertain of the future protection of such innovation. I'm looking forward to hearing from government agencies, the judiciary, in-house and outside counsel regarding various considerations impacting the future of patent procurement as well as patent enforcement."

Leaders from both brand and generic drug companies recognize that this event serves both sides of the industry and offers both legal and economic "take aways" for every sphere of this costly, complex and evolving litigation.

Full information on the event, visit: http://bit.ly/3SDeANQ

# # #

A unique organization, American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world.